Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alkermes To Fly Solo On Vivitrol After Cephalon’s Departure

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech cites need to educate physicians about long-acting injectable for alcohol dependence.

You may also be interested in...



Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak

The CNS specialist outlined long-term commercial prospects for four drugs in its “emerging blockbuster” portfolio during an investor day presentation. The company also unveiled a new clinical candidate, a drug for the treatment of Alzheimer’s agitation.

With Alkermes’ Transition Well Under Way, Commercial Expansion Is Next

As Alkermes advances its proprietary pipeline, the company is beginning to build its commercial organization ahead of what will be the launch of its first wholly owned drug since it took the marketing reins with Vivitrol in 2008.

For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love

Underreporting of adverse events may be a Russian "cultural norm," the agency says in a briefing document released in advance of an advisory panel review of Alkermes' Vivitrol (naltrexone) for opioid dependence.

Related Content

Topics

UsernamePublicRestriction

Register

PS067097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel